Optimi™ LABS

accelerating innovation

Our in-house facility is designed to accelerate agricultural innovation, advanced agronomy, and improved efficiencies in production and product development.
Through strategic partnerships with academic institutions, professional researchers and scientific leaders, Optimi Labs intends to add value through intellectual property development, specialty formulations, growth optimization and studies on enhanced physical and mental performance development.

Key functions

  • Optimize commercial cultivation processes
  • Improve strain quality & yield
  • Improve extraction efficiencies
  • Fungi extract innovation
  • Product development
  • Innovation in human delivery mechanisms
  • Synthetic and non-synthetic compound exploration
  • Pharmaceutical development & new drug formulation research
  • Active compound investigation


Our initial focus is on the research and development of functional mushrooms (non-psychedelic) cultivation and extraction.
Then advancing into research into mushroom-derived psilocin/psilocybin which is designed to investigate the treatment of mental illness, addiction, and other health conditions if and as permitted by applicable laws, pursuant to the Research Exemption and/or Dealer’s License.


To expedite innovation, 
Optimi™ Labs works with
both academic and strategic development partnerships.

Optimi™ Labs is developing an intellectual property (IP) strategy encompassing delivery mechanisms, as the champions of natural, extraction methods, isolation of chemical compounds, new formulations, testing and protocol regimens specific to mushroom based products.


To accelerate our research prior to the receipt of the Dealer’s License, Optimi aims to commission a number of research and development projects related to psychedelic compounds.
To this end, Optimi entered into an agreement with Numinus Wellness Inc. to provide certain psychedelic research, development and testing services. Numinus holds a Health Canada Dealer’s License and all activities proposed under the Company’s arrangement with Numinus will be carried out by Numinus personnel at its facility in compliance with its Dealer’s License requirements. All resulting Intellectual Property (IP) to be owned 100% by Optimi.

Leading, testing, and participating in research and clinical studies that identify proprietary solutions that help solve human disease and optimize human potential.

Clinical Trials Academic Consultants

The Company has also entered into a Master Consulting Agreement (“MCA”) with UTI Limited Partnership (“Innovate Calgary”), the innovation transfer and business incubator centre for the University of Calgary. Innovate Calgary is an incubator designed to provide consulting services that assists ventures in the life sciences or biomedical industries with: (a) reviewing, designing, planning and/or conducting clinical trial studies, (b) presenting data generated from clinical trial studies, and/or (c) seeking clinical trial-related services from third parties. Under the MCA and first Statement of Work, Innovate Calgary will design and carry out a clinical trial in respect of the potential health and wellness applications of the Company’s products and proposed products, expected to be completed within one year.

Development Opportunity – Psilocybin

Scientific interest in classic psychedelics, such as psilocybin, has returned and grown because of several promising studies, validating earlier research. For mood and anxiety disorders, three controlled trials have suggested that psilocybin may decrease symptoms of depression and anxiety in the context of cancer-related psychiatric distress for at least 6 months following a single acute administration. A small, open-label study in patients with treatment resistant depression showed reductions in depression and anxiety symptoms three months after two acute doses. For addiction, small, open-label pilot studies have shown promising success rates for both tobacco and alcohol addiction. Safety data from these various trials, which involve careful screening, preparation, monitoring, and follow-up, indicate the absence of severe drug-related adverse reactions (Source: Johnson & Griffiths, 2017). Based on a recent report by Data Bridge Market Research, Market Analysis Study, 2020, the psychedelic drug market is growing with a compound annual growth rate of 16.3% and expected to reach USD $6.9 billion by 2027. Optimi’s goal is to become strategically positioned as a producer and distributor of medical psilocybin and other psychedelic/nutraceutical products, where permitted by applicable laws.

LEarn more about our operations


Sign up for free News Alerts